Zelluna ASA Logo

Zelluna ASA

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Health Care
Industry:
Biotechnology

Description

Zelluna’s mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs that have taken immune-oncology projects from inception through to the clinic and supported by a highly experienced international board We are committed to provide benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that we believe has the potential to be both safe and potent. This platform has unique advantages providing “off-the-shelf” access to an advanced therapy for large patient populations.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Regulatory News Service
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Regulatory News Service
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Regulatory News Service
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Regulatory News Service
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Regulatory News Service
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB
2025-04-29 12:50
Regulatory News Service
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 1.4 KB
2025-04-22 05:47
Inside Information Statement
Zelluna Reaches Major Milestone with Manufacturing Process Established in Prepa…
English 6.3 KB
2025-04-08 06:43
Regulatory News Service
Financial calendar
English 681 bytes
2025-04-04 13:21
Directors' Dealings
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary i…
English 86.5 KB
2025-04-04 13:21
Directors' Dealings
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary i…
English 2.9 KB
2025-04-04 05:00
Regulatory News Service
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025
English 116.4 KB
2025-04-04 05:00
Regulatory News Service
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025
English 341.2 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Herantis Pharma Oyj Logo Herantis Pharma Oyj Finland HRTIS
Hiron-Trade Investments & Industrial Buildings Ltd. Israel HRON
Human Stem Cells Institute PJSC Logo Human Stem Cells Institute PJSC Russian Federation ISKJ
Human Xtensions Ltd. Logo Human Xtensions Ltd. Israel HUMX
Hybrigenics SA Logo Hybrigenics SA France ALHYG
Hyloris Pharmaceuticals SA Logo Hyloris Pharmaceuticals SA Belgium HYL
Ikonisys S.A. Logo Ikonisys S.A. France ALIKO
IMCB PJSC Logo IMCB PJSC Russian Federation GEMA
Inify Laboratories AB Logo Inify Laboratories AB Sweden INIFY
Innate Pharma Logo Innate Pharma France IPH